Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

19.12USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$19.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
402,889
52-wk High
$21.95
52-wk Low
$3.85

Chart for

About

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $1,796.08
Shares Outstanding(Mil.): 93.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

Nov 02 2017

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

Oct 30 2017

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

Oct 10 2017

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

Sep 29 2017

BRIEF-Spectrum Pharma starts phase 3 qapzola trial

* Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc)

Aug 14 2017

BRIEF-Spectrum Pharma enters into an at market issuance sales agreement

* Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing

Aug 04 2017

BRIEF-Spectrum Pharmaceuticals Q2 loss per share $0.26

* Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update

Aug 03 2017

BRIEF-Spectrum Pharmaceuticals announces ‍enrollment in Rolontis phase 3 advance pivotal study​

* Spectrum Pharmaceuticals Inc - ‍enrollment with 405 patients randomized in rolontis phase 3 advance pivotal study​

Aug 01 2017

BRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting

* Spectrum Pharmaceuticals Inc - stockholders did not approve by advisory vote executive compensation at annual meeting Source text: (http://bit.ly/2sHq6yo) Further company coverage:

Jun 16 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $137.93 -0.07
Pfizer Inc. (PFE.N) $35.35 -0.02
Novartis AG (NOVN.S) CHF82.75 -0.35
Merck & Co., Inc. (MRK.N) $54.10 -1.10
Roche Holding Ltd. (ROG.S) CHF242.90 -0.70
Roche Holding Ltd. (RO.S) CHF244.40 -1.60
Abbott Laboratories (ABT.N) $55.29 -0.27
Bayer AG (BAYGn.DE) €108.50 -0.15
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.47 -0.28

Earnings vs. Estimates